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Abstract
Purpose of Review This review highlights problems related to translation of advanced therapy medicinal products (ATMPs) from
bench to bedsite. Regenerative medicine within the current regulatory frame reveals common hitches in the course of develop-
ment, translation, and clinical application. This paper suggests outlining a path from the few examples of successfully approved
vs unsuccessful advanced therapies.
Recent Findings In the multitude of ongoing studies, few of them achieved positive results with a final treatment available to
patients; this result was possible due to multidisciplinary teams working together from the beginning of the development and
during the hard route to standardization and clinical application.
Summary The root of success of an advanced therapy requires not only the inescapable scientific and biological knowledge but
also requires several contributions as regulatory, ethical, medical, and bio-engineering expertise, from the real beginning. A
strong scientific rationale and an integrated network of expertises would contribute to a successful investment of available
resources in advanced therapy medicinal products and to a greater confidence in future medicine.
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Introduction
Stem cell transplantation has raised great expectations for ful-
filling unmet medical needs, and substantial resources have
been invested to explore stem cell applications and develop
novel therapies. Despite the impressive technological evolu-
tion, only a limited percentage of these studies has reached
clinical application and only few of them have obtained pos-
itive results [1, 2, 3•, 4•].
The resulting picture is a technology with great potential
that is being viewed with skepticism and a progressive lack of
confidence.
The analysis of failures and the related “valley of death”,
which is also described for chemical drugs, has produced a
biased description of causes: scientists ascribe setbacks to
technicalities and shortage of funding, entrepreneurs blame
scientists for insufficient long-term planning and lack of data
reproducibility, regulators criticize the lack of accuracy in
quality or safety evaluations, patients complain of the absence
of therapies for severe diseases, and governments bemoan the
increasing health costs. What is the real problem? Is it the sum
of all of the above?
Most root cause analyses are biased since they describe a
single perspective, revealing that cross-fertilization is missing,
even though many interdisciplinary meetings have been con-
ducted. Inappropriate communication between different pro-
fessionals having their own priorities and technical languages
has been frequently observed.
It is clear that specific experts hold leading positions in
different phases of development for a new stem cell therapy:
scientists in the early phase of research; physicians in clinical
trials; and entrepreneurs in the evaluation of opportunities,
organization, and funding; as well as public payers and regu-
lators in the reviewing of preclinical and clinical data. They
are all involved in the translation and forming the “tower of
Babel” and contributing to the valley of death (Fig. 1).
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From a scientific viewpoint, research is usually conducted
to define the experimental condition and observe/understand
cell behavior. Shifting this attitude toward controlling the con-
ditions in order to develop a specific product is not easy. This
difference can produce variability and problems in standardi-
zation. Taking control of manufacturing conditions requires a
very deep knowledge of the process, and the pressure to “pub-
lish or perish” can result in inaccurate or fake research. In
addition, scientific journals primarily publish positive results,
and failures are rarely reported. Further, data are usually de-
scribed in a limited number of words, not listing all the tech-
nical details critical for product reproducibility.
In case of cell therapies that often involve extensive cell
manipulation, the regulatory requirements should be consid-
ered from the real beginning (planning) of research. The def-
inition of experimental conditions for therapeutic develop-
ment should only include materials with a “clinical level”
safety profile, and should, therefore, be produced by organ-
isms or processes in which disease transmission, toxicity, or
impurities could be controlled. Tissues should be
manufactured reproducibly and possibly reagents should not
leave detectable residues in the final cell preparation adminis-
tered to patients.
The number of replicates produced for scientific papers are
usually insufficient for clinical translation, where a quantita-
tive description of all parameters is required despite the pos-
sible high biological variability in the general population.
In a typical case, if the expression of a specific cell param-
eter increases by 30% in the culture phase, the lower and
upper limit of expression should be defined in cell therapy
protocols intended for clinical application; a standard question
could be 28–32% or 10–40%? How was the interval defined?
How to validate the assays for detection and quantification?
What is a possible reference standard for the marker in the
validation assay?
The answers to these questions require a large number of
replicates to balance biological variability defining the limits
applicable to many different individuals and considering a
“safety margin.”
Since the complete exercise is not easy, successful exam-
ples of regulatory approval and transplantation for both cell
and gene therapies should provide a track for other future
therapies.
Here, we report some examples from the developmental
phases of successful and failed tissue engineering products,
i.e., Holoclar® [1] and tracheal reconstruction [5], and two
successful examples of gene therapy, i.e., a registered product
(Strimvelis®) [3•] for the treatment of ADA deficiency and a
phase I/II trial for the treatment of junctional epidermolysis
bullosa [6].
Early Phase and Planning
In Europe, stem cell cultures are considered as advanced ther-
apy medicinal products. Therefore, they need to be compliant
with (European Medicinal Agency) cGMP rules. The GMP
rules cannot include anything that is not validated or not pro-
duced following the “quality” criteria. Cell cultures including
stem cells may need many different components, such as se-
rum (of animal or human origin) or simply culture medium
and growth factors that are not always produced for human
use. On the same note, most of these components are not
included in the pharmacopeia. Therefore, no “official” assay
for their control is envisaged and it becomes a scientist’s role
to propose a safe origin for each component, GMP-compliant
assays, and a reference standard for their control.
Thus, knowledge of these rules is mandatory for the scien-
tist from the beginning of the research.
This further implies that the development of these therapies
should foresee the training of biologists on regulatory rules,
from the beginning of their education (or at least before de-
veloping the therapies).
Fig. 1 Translation of ATMP from bench to bedsite. The different phases of development for a new stem cell therapy
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This is not commonly done, leading to development of
putative therapies, which need to be completely redefined lat-
er, with an increase in failures, time, and costs.
The types of controls on raw materials for advanced thera-
py planning should be based not only on the risks related to
contaminants and impurities but also on their capacity to
maintain biological functions relevant to the foreseen mecha-
nism of action of the product. In the case of stem cell products,
it means that no reagent should interfere with the ability of
these specific cells to form a tissue and to maintain their ca-
pacities over their lifetime. In the case of advanced therapies
approved at the European level, “in-process controls”measur-
ing the expression of markers/properties validated for their
correlation with stem cell-specific functions, such as prolifer-
ative potential in vitro and successful in vivo regeneration
properties, are envisaged. These are different from the assess-
ment of active proliferation as they are a measure of the ca-
pacity to maintain proliferation over the lifetime of the culture
and in vivo. In the case of gene therapy [7], long-term expres-
sion of the transgene that is missing or defective in the pathol-
ogy should also be included as an in-process control.
In the case of the proposed examples of advanced therapy
medicinal products, the “regulatory controls” on rawmaterials
were not in place in the early phase of the research, as they
were developed before the ATMP regulation was passed in
Europe. However, it should be noted that a significant number
of basic research investigations were conducted for three of
these ATMPs, namely Holoclar®, Strimvelis®, and junctional
epidermolysis bullosa treatment before their clinical ap-
plication, and many investigations were also conducted
on the cell identification and their specific properties
[8•, 9•, 10].
In the case of tracheal reconstruction, these studies ap-
peared insufficient for a reproducible and efficient ATMP.
One critical issue for cell therapy development is the
potency assay, requested by regulatory authorities and
defined in the ICH Q6B guideline [11] as a “measure
of the biological activity using a suitable quantitative
biological assay, based on the attribute of the product
which is linked to the relevant biological properties”.
This request comes from the past when elucidation of
drug structure was limited and the measure of “content”
was requested as quantification of biological activity
related to structural integrity [12]. In stem cell therapy
as well as for all ATMPs, biological activity can involve
multiple pathways, and therefore, scientists should iden-
tify a “tailored” assay including activities possibly relat-
ed to function. In other words, a relationship between
the results of selected assays and their clinical effect
(efficacy/safety) is expected. This prospect implies that
the scientist would know what and how much a specific
cell function is responsible for the mechanism of action
of the therapy.
This knowledge is usually confirmed after clinical applica-
tion, when the mechanism of action is fully understood. Once
the potency assay is identified, it becomes instrumental for the
evaluation of the drug/therapy, the manufacturing process
changes, the release approval, the stability, and so on. Indeed,
any alteration in cell performance could be easily highlighted
by a comparative measure of potency, allowing appropriate
selection of conditions and control of their maintenance.
The registered stem cell product, Holoclar®, identified a
specific stem cell marker, p63, used as a potency assay since
its mechanism was to replace lost stem cells [8•, 13]. The gene
therapy products (Strimvelis®) and the epidermolysis bullosa
treatment proposed the percentage of transduction with the
transgene associated with the quantitative measure of capacity
for tissue regeneration: CD34 and colony forming efficiency,
respectively [6, 14]. No potency marker is known for the
tracheal reconstruction.
In the timeline, all in-process controls are defined and run
early in the process development. Therefore, functions and
marker maintenance as well as their correlation with in vivo
behavior need to be identified well before their clinical appli-
cation, in adequate models for product testing.
This implies that a significant number of basic research
investigations should be conducted before planning the clini-
cal application of any specific model.
Preclinical Study
The preclinical phase can be run on relevant animal models if
any, integrated with in vitro prototypes, or using in vitro sys-
tems only. The use of autologous cultured animal cell trans-
plantation cannot provide many safety indications, as fre-
quently animals present substantial differences in stem cell
culture conditions, microenvironment, and distribution with
respect to human tissues [15, 16]. In addition, the size of the
tissue is frequently different and is related to the cell dosage
and microenvironment. Use of this approach would lead to the
need of repetition for all settings of the therapy in human
conditions with the loss of time and costs.
The problem with animal models is a significant issue for
stem cell products because in parallel to high costs, xenotrans-
plantation can result in poor engraftment where the safety of
the treatment (due to in vivo cell behavior) is not properly
highlighted.
Typically, in vivo models are used for evaluating the
biodistribution of transplanted cells and the analysis of uncon-
trolled cell growth due to improper extensive manipulation.
For both, integration of cells in the model is mandatory for
safety evaluation.
It was proven that the repair of some very severe lesions
was due to the engraftment of cultured cells and not to “cir-
culating” cells. This was coherently shown in gene therapy
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treatments where autologous cells are genetically different
from the resident cells and are found to repopulate the entire
tissue after culture and transplant [4•]. Examples include
ADA-deficiency treatment with genetically modified CD34+
blood cells or junctional epidermolysis bullosa therapy with
LM5-beta 3-transduced epidermal cells, after approximately
10 years of follow-up in both cases [6, 14, 17].
Indeed, animal models would have no meaning for safety
evaluation without a proven engraftment of transplanted cells.
The tissue physiology in different animal species can be an
obstacle for understanding human stem cell behavior. In the
case of at least two gene therapy protocols, the absence of
resident stem cells was shown as a pre-requisite for transduced
cell engraftment and efficacy. This also holds true for other
safety evaluations, where transplanted stem cell tumorigenic-
ity cannot be evaluated properly, in the presence of mixed
human and animal cells producing a variable rate of integra-
tion and a different microenvironment. The experience with
the epidermolysis bullosa treatment revealed an absence of
migration in the integrated, GFP-labeled human cells in the
animal model [18]. Conversely, the model failed to reproduce
human cell integration for Holoclar (data not shown), and the
published data on trachea did not report the dramatic failures
shown in humans, when the tissue was tested in animals [19].
In the case of Strimvelis® where the migration occurs in the
physiology of hematopoietic tissues, the absence of uncon-
trolled proliferation was proven [20–22]. Thus, the use of
human in vitro models is probably desirable for a realistic
evaluation of any therapy.
On this line, it is necessary to make specific distinctions
when using embryonic or induced pluripotent stem cells.
These cells are committed to differentiation into specific tis-
sues before in vivo transfer; when few uncommitted cells per-
sist, in vivo models can highlight the development of terato-
mas, which could be not so evident in vitro.
On the other hand, commitment should not be driven up to
somatic stem cell loss in order to preserve tissue self-renewal.
This issue can be easily highlighted and characterized by in-
tegration with in vitro models. Finally, the additional use of
human in vitro models has several advantages such as increas-
ing the knowledge of tested ATMPs, the biological behavior
of the tissue, and not least, the cost optimization before clinical
application.
Clinical Application
A specific clinical question is usually defined at the real be-
ginning of the study. This is one of the most important phases
of a study, as poorly focused questions lead to unclear
decisions.
The study of clinical applications allows the definition of
formulations compatible with putative surgery, mode of
administration, and patient selection. Identification of a real
unmet medical need should drive meaningful research
through which patients and health care professionals bring in
new insights with respect to research priorities, treatment, and
outcomes. All relevant parties should be involved in this phase
defining the clinical questions, developing the trial protocol,
and commenting on the preliminary design.
The evaluation is related to risk/benefit ratio as well as to
whether a medicine is cost effective in relation to other treat-
ment alternatives, answered in the social context.
For low levels of severity in different pathologies, treat-
ments are frequently available but few or no alternatives are
in place for the highest severity score. This implies that the
selection of patients as well as the definition of ATMP clinical
outcomes should be indicated for a specific threshold of in-
clemency. Indeed, patient group differences, in particular, the
differential baseline risk of the condition and the capacity of
different subgroups of patients to benefit, must be considered.
One example comes from cartilage repair. There are differ-
ent treatment options for cartilage defects, depending on de-
fect size and the state of the subchondral bone. Cartilage de-
fects can be treated by surgery, bone marrow-stimulating tech-
niques, osteochondral autograft transplantation, or implanta-
tion of cells and/or scaffolds. Autologous chondrocyte im-
plantation (ACI) and scaffold-supported ACI are often used
for treating large chondral defects (> 2 cm2), where other treat-
ment options would be ineffective [23].
Clinical trials for ATMPs should include almost exclusive-
ly severe lesions for which repair is more challenging than for
mild lesions. However, the consequence is a lower expectation
for the related clinical outcome in a cost/benefit ratio evalua-
tion. This applies (as an example) to urethral stenosis: some
forms of these have a high success rate with surgery, but others
have a very high failure rate due to lichen sclerosus or failure
after hypospadia treatment, resulting in disability and requir-
ing new therapeutic approaches [24].
In the case of Holoclar®, Strimvelis®, and the phase I/II
junctional epidermolysis bullosa treatment, the patient selec-
tion criteria were very well-defined and selection was based
on either a precise definition of pathology associated to an
accurate grading or a genetic diagnosis of the affected individ-
uals [6, 8•, 14]. The tracheal pathologies highlighted a signif-
icant unmet medical need for reconstruction but the applied
selection of patients was too wide and includedmany different
conditions [25].
When the outcomes of clinical and pharmaco-economic
analyses are not properly defined or not considered by clini-
cians or scientists, problems are raised at a later stage by reg-
ulators and payers.
Concerning medicine formulation, severely damaged
wound beds require different surgery as well as different stem
cell products, i.e., the presence of carrier, substrate or cells
only, whole tissue or layers of cells, enrichment of stem cells,
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or a defined ratio between stem and differentiated cells.
Different therapeutic formulations could apply to the same
tissue, depending on the pathology, surgery, and the resulting
wound bed, and requires an accurate analysis. For example,
epithelial cells from the cornea are usually cultured and
transplanted with a carrier due to the fragility of the cultured
corneal epithelium [26], whereas epithelium from the airway
was cultured on a scaffold to reconstitute the trachea [27].
Vitiligo treatments have been proposed using cells
(melanocytes) or epithelium only, due to the need for rapid
engraftment to superficial lesions [28]. Epithelia are usually
transplanted with a defined proportion of stem and differenti-
ated cells to quickly provide a barrier and to maintain the
normal tissue homeostasis. In the case of bone marrow, a stem
cell-enriched fraction is transplanted, since the mechanism of
action envisages a rapid recolonization of the niche [29]. All
these different choices have implications on cell therapy de-
velopment together with an accurate testing of long-term com-
patibility of putative carriers and cell/scaffold interaction
with ancillary drugs administered to the specific selection
of patients. An optimal design should be considered, even
for effectiveness needs, and activities must be implement-
ed in the early stage of research, through collaboration of
biologists and clinicians, as in previously mentioned suc-
cessful therapies.
Additional Issues
It is difficult to complete the list of hurdles preventing the
efficient translation of ATMPs. However, some additional is-
sues need to be considered. Two of these include the training
of clinical teams on GMP rules and the administration of
ATMPs. The GMP rules in force for ATMPs require well-
defined procedures for all activities and extensive reporting.
Specific training is thus needed for the clinical team in order to
enable physicians, surgeons, and nurses to properly manage
all the requested documents. The issue of ATMP administra-
tion and handling requires a specific knowledge of the prod-
uct, its fragility, and the limitations related to the use of an in
vitro-assembled, actively proliferating tissue, which is differ-
ent from the standard whole-tissue transplant. To guarantee
efficient translation, the presence of a medical service provid-
ing knowledge on the product specificities is desirable both
from the viewpoint of regulators and the clinical team. This
approach was followed for Holoclar® and the epidermolysis
bullosa products, and specific training was provided to a sin-
gle teammanaging the therapy for Strimvelis® and for trache-
al reconstruction.
Finally, the problem of cost containment must be consid-
ered. The choice between organizations under hospital ex-
emption or company fell on a mixed regime for three of the
selected examples. Holoclar®, Strimvelis®, and the
junctional epidermolysis bullosa treatment began their re-
search and in-depth investigations on the product in a free
research environment under hospital exemption and opted
for a company setting at the time of registration and distribu-
tion, when industrial knowledge was essential to ensure wide-
spread use of the technologies. Trachea reconstruction was
always performed under hospital exemption, but never
achieved a wide distribution.
Undoubtedly, cost minimization will change dramatically
when the entire planning of ATMP development will not need
duplication, as was seen before/after the introduction of GMP
and regulatory rules. The cost profile will be reduced when
surgeons and biologists will begin development by consider-
ing the rules. Additional support will be obtained from sharing
resources and responsibility, as in the case of private-public
partnerships, and by tailored automation and scaling up of
production.
Conclusion
The clinical translation of medically promising cell and gene
therapy approaches has been slow and expensive and has
shown poor efficiency. In part, clinical translation has been
hampered by biased research practices that lead to publication
of studies with low reproducibility. These include small, non-
predictive studies; improperly designed studies, especially
those with biased or undefined clinical experimental groups
and lacking necessary controls; studies using uncharacterized
or poorly characterized cells and materials, a low number of
replicates, or non-validated methods; studies conducted with a
poor understanding of the relevant biology and mechanisms;
and studies lacking interdisciplinarity. The problems are fur-
ther compounded by a culture that does not incentivize shar-
ing but encourages poor or selective reporting, the high costs
of materials and equipment, and poor flexibility of companies
in the application of new approaches to the development of
ATMP products. In this review, we discussed some of these
problems in light of successful and unsuccessful examples of
gene and cell therapy and provided mitigating strategies.
Progress on reducing bias, enhancing reproducibility, and
investing in multidisciplinary education with an in-depth anal-
ysis of processes and pathologies should enhance the transla-
tional potential of preclinical technologies.
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